Chromogranin A pathway: from pathogenic molecule to renal disease
- 12 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 38 (3), 456-466
- https://doi.org/10.1097/hjh.0000000000002295
Abstract
Chromogranin A (CHGA) is an index granin protein critical for biogenesis and exocytotic release of catecholamine storage granules. It is elevated in plasma of patients with sympathetic over-activity and kidney dysfunction. Several CHGA polymorphisms are associated with hypertensive kidney disease. Previously, we unraveled the molecular mechanism by which CHGA expression is regulated in African Americans carrying a genetic variation associated with hypertensive chronic kidney disease (CKD). Experimental CKD mouse model were created by 5/6th nephrectomy (Npx) using wild-type and Chga−/− knockout mouse strains to delineate the role of CHGA in CKD. Wild-type-Npx mice expressing Chga developed exacerbated azotemia and fibrosis as compared with their knockout-Npx counterparts. Gene expression profiling revealed downregulation of mitochondrial respiratory complexes genes consistent with maladaptive mitochondria in wild-type-Npx mice, contrasted to knockout-Npx. In healthy individuals, an inverse relationship between circulating CHGA levels and glomerular function was observed. In vitro, mesangial cells treated with CHGA-triggered nitric oxide release by a signaling mechanism involving scavenger receptor SR-A. The CHGA-treated and untreated mesangial cells displayed differential expression of cytokine, chemokine, complement, acute phase inflammatory and apoptotic pathway genes. Thus, build-up of plasma CHGA because of kidney injury served as an insult to the mesangial cells resulting in expression of genes promoting inflammation, fibrosis, and progression of CKD. These findings improve understanding of the role of elevated CHGA in the progression of CKD and reveal novel pathways that could be exploited for therapeutic strategies in hypertensive kidney disease.This publication has 47 references indexed in Scilit:
- MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertensionHuman Molecular Genetics, 2013
- Naturally Occurring Genetic Variants in Human Chromogranin A (CHGA) Associated with Hypertension as well as Hypertensive Renal DiseaseCellular and Molecular Neurobiology, 2010
- Common Genetic Variants in the Chromogranin A Promoter Are Associated with Renal Injury in IGA Nephropathy Patients with Malignant HypertensionRenal Failure, 2010
- Chromogranin A Regulates Renal Function by Triggering Weibel–Palade Body ExocytosisJournal of the American Society of Nephrology, 2009
- Naturally Occurring Human Genetic Variation in the 3′-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent FashionJournal of Invasive Cardiology, 2008
- Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressureKidney International, 2008
- Chromogranin A Polymorphisms Are Associated With Hypertensive Renal DiseaseJournal of the American Society of Nephrology, 2008
- Genetic Variation of the Renin-Angiotensin System and Chronic Kidney Disease Progression in Black Individuals in the Atherosclerosis Risk in Communities StudyJournal of the American Society of Nephrology, 2006
- Inferences, questions and possibilities in Toll-like receptor signallingNature, 2004
- Chromogranin A in Human HypertensionHypertension, 1995